Skip to main content
Top
Published in: Lung 6/2015

01-12-2015

Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation

Authors: Liesbeth ten Klooster, George D. Nossent, Johanna M. Kwakkel-van Erp, Diana A. van Kessel, Erik J. Oudijk, Ed A. van de Graaf, Bart Luijk, Rogier A. Hoek, Bernt van den Blink, Peter Th. van Hal, Erik A. Verschuuren, Wim van der Bij, Coline H. van Moorsel, Jan C. Grutters

Published in: Lung | Issue 6/2015

Login to get access

Abstract

Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrosing lung disease with a median survival of approximately 3 years after diagnosis. The only medical option to improve survival in IPF is lung transplantation (LTX). The purpose of this study was to evaluate trajectory data of IPF patients listed for LTX and to investigate the survival after LTX.

Methods and Results

Data were retrospectively collected from September 1989 until July 2011 of all IPF patients registered for LTX in the Netherlands. Patients were included after revision of the diagnosis based on the criteria set by the ATS/ERS/JRS/ALAT. Trajectory data, clinical data at time of screening, and donor data were collected. In total, 98 IPF patients were listed for LTX. During the waiting list period, 30 % of the patients died. Mean pulmonary artery pressure, 6-min walking distance, and the use of supplemental oxygen were significant predictors of mortality on the waiting list. Fifty-two patients received LTX with a median overall survival after transplantation of 10 years.

Conclusions

This study demonstrated a 10-year survival time after LTX in IPF. Furthermore, our study demonstrated a significantly better survival after bilateral LTX in IPF compared to single LTX although bilateral LTX patients were significantly younger.
Literature
1.
go back to reference Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed
2.
3.
go back to reference Chan AL, Rafii R, Louie S et al (2013) Therapeutic update in idiopathic pulmonary fibrosis. Clin Rev Allergy Immunol 44:65–74CrossRefPubMed Chan AL, Rafii R, Louie S et al (2013) Therapeutic update in idiopathic pulmonary fibrosis. Clin Rev Allergy Immunol 44:65–74CrossRefPubMed
4.
go back to reference Thabut G, Christie JD, Ravaud P et al (2009) Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 151:767–774CrossRefPubMed Thabut G, Christie JD, Ravaud P et al (2009) Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 151:767–774CrossRefPubMed
5.
go back to reference Hosenpud JD, Bennett LE, Keck BM et al (1998) Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 351:24–27CrossRefPubMed Hosenpud JD, Bennett LE, Keck BM et al (1998) Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 351:24–27CrossRefPubMed
7.
go back to reference Stehlik J, Edwards LB, Kucheryavaya AY et al (2012) The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant 31:1052–1064CrossRefPubMed Stehlik J, Edwards LB, Kucheryavaya AY et al (2012) The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant 31:1052–1064CrossRefPubMed
8.
go back to reference Nathan SD, Shlobin OA, Weir N et al (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140:221–229CrossRefPubMed Nathan SD, Shlobin OA, Weir N et al (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140:221–229CrossRefPubMed
9.
go back to reference Song JW, Hong SB, Lim CM et al (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–363CrossRefPubMed Song JW, Hong SB, Lim CM et al (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–363CrossRefPubMed
10.
go back to reference Whelan TP, Dunitz JM, Kelly RF et al (2005) Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 24:1269–1274CrossRefPubMed Whelan TP, Dunitz JM, Kelly RF et al (2005) Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 24:1269–1274CrossRefPubMed
11.
go back to reference Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087CrossRefPubMed Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087CrossRefPubMed
12.
go back to reference Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769CrossRefPubMed Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769CrossRefPubMed
13.
go back to reference Taniguchi H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829CrossRefPubMed Taniguchi H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829CrossRefPubMed
14.
go back to reference Nathan SD, Shlobin OA, Ahmad S et al (2010) Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. J Heart Lung Transplant 29:1165–1171CrossRefPubMed Nathan SD, Shlobin OA, Ahmad S et al (2010) Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. J Heart Lung Transplant 29:1165–1171CrossRefPubMed
15.
go back to reference Rinaldi M, Sansone F, Boffini M et al (2008) Single versus double lung transplantation in pulmonary fibrosis: a debated topic. Transplant Proc 40:2010–2012CrossRefPubMed Rinaldi M, Sansone F, Boffini M et al (2008) Single versus double lung transplantation in pulmonary fibrosis: a debated topic. Transplant Proc 40:2010–2012CrossRefPubMed
16.
go back to reference Meyer DM, Edwards LB, Torres F et al (2005) Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 79:950–957; discussion 957–958 CrossRefPubMed Meyer DM, Edwards LB, Torres F et al (2005) Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 79:950–957; discussion 957–958 CrossRefPubMed
17.
go back to reference Neurohr C, Huppmann P, Thum D et al (2010) Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int 23:887–896PubMed Neurohr C, Huppmann P, Thum D et al (2010) Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int 23:887–896PubMed
18.
go back to reference Mason DP, Brizzio ME, Alster JM et al (2007) Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 84:1121–1128CrossRefPubMed Mason DP, Brizzio ME, Alster JM et al (2007) Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 84:1121–1128CrossRefPubMed
19.
go back to reference Algar FJ, Espinosa D, Moreno P et al (2010) Results of lung transplantation in idiopathic pulmonary fibrosis patients. Transplant Proc 42:3211–3213CrossRefPubMed Algar FJ, Espinosa D, Moreno P et al (2010) Results of lung transplantation in idiopathic pulmonary fibrosis patients. Transplant Proc 42:3211–3213CrossRefPubMed
20.
go back to reference Weiss ES, Allen JG, Merlo CA et al (2009) Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann Thorac Surg 88:1616–1625; discussion 1625–1626 CrossRefPubMed Weiss ES, Allen JG, Merlo CA et al (2009) Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann Thorac Surg 88:1616–1625; discussion 1625–1626 CrossRefPubMed
21.
go back to reference Force SD, Kilgo P, Neujahr DC et al (2011) Bilateral lung transplantation offers better long-term survival, compared with single-lung transplantation, for younger patients with idiopathic pulmonary fibrosis. Ann Thorac Surg 91:244–249PubMedCentralCrossRefPubMed Force SD, Kilgo P, Neujahr DC et al (2011) Bilateral lung transplantation offers better long-term survival, compared with single-lung transplantation, for younger patients with idiopathic pulmonary fibrosis. Ann Thorac Surg 91:244–249PubMedCentralCrossRefPubMed
22.
go back to reference Meyers BF, Lynch JP, Trulock EP et al (2000) Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 120:99–107CrossRefPubMed Meyers BF, Lynch JP, Trulock EP et al (2000) Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 120:99–107CrossRefPubMed
23.
go back to reference Thabut G, Mal H, Castier Y et al (2003) Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 126:469–475CrossRefPubMed Thabut G, Mal H, Castier Y et al (2003) Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 126:469–475CrossRefPubMed
24.
go back to reference Keating D, Levvey B, Kotsimbos T et al (2009) Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc 41:289–291CrossRefPubMed Keating D, Levvey B, Kotsimbos T et al (2009) Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc 41:289–291CrossRefPubMed
25.
go back to reference Navaratnam V, Ali N, Smith CJ et al (2011) Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis? Respir Med 105:1925–1930CrossRefPubMed Navaratnam V, Ali N, Smith CJ et al (2011) Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis? Respir Med 105:1925–1930CrossRefPubMed
26.
go back to reference Monaghan H, Wells AU, Colby TV et al (2004) Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 125:522–526CrossRefPubMed Monaghan H, Wells AU, Colby TV et al (2004) Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 125:522–526CrossRefPubMed
27.
go back to reference Orens JB, Estenne M, Arcasoy S et al (2006) International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745–755CrossRefPubMed Orens JB, Estenne M, Arcasoy S et al (2006) International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745–755CrossRefPubMed
28.
go back to reference Kreider M, Hadjiliadis D, Kotloff RM (2011) Candidate selection, timing of listing, and choice of procedure for lung transplantation. Clin Chest Med 32:199–211CrossRefPubMed Kreider M, Hadjiliadis D, Kotloff RM (2011) Candidate selection, timing of listing, and choice of procedure for lung transplantation. Clin Chest Med 32:199–211CrossRefPubMed
29.
go back to reference du Bois RM, Weycker D, Albera C et al (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:459–466CrossRefPubMed du Bois RM, Weycker D, Albera C et al (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:459–466CrossRefPubMed
Metadata
Title
Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation
Authors
Liesbeth ten Klooster
George D. Nossent
Johanna M. Kwakkel-van Erp
Diana A. van Kessel
Erik J. Oudijk
Ed A. van de Graaf
Bart Luijk
Rogier A. Hoek
Bernt van den Blink
Peter Th. van Hal
Erik A. Verschuuren
Wim van der Bij
Coline H. van Moorsel
Jan C. Grutters
Publication date
01-12-2015
Publisher
Springer US
Published in
Lung / Issue 6/2015
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-015-9794-7

Other articles of this Issue 6/2015

Lung 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.